Pharmacokinetics of glycyrrhizin in normal and albumin-deficient rats

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 7, 2008, Pages 373-381

  Koga, Kenjiro ^a   Tomoyama, Michiko ^a   Ohyanagi, Kazuo ^a   Takada, Kanji ^b  

^a HOKURIKU UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Analbuminemic rat; Chronic hepatitis; Glycyrrhizin; Protein binding; Serum albumin

Indexed keywords

ALBUMIN; CHLORAMPHENICOL; GLYCYRRHIZIC ACID; ANTIINFLAMMATORY AGENT; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ANALBUMINEMIA; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG PROTEIN BINDING; FEMALE; NONHUMAN; RAT; STEADY STATE; ANIMAL; BILE; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MALE; METABOLISM; PROTEIN BINDING; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BILE; GLYCYRRHIZIC ACID; HEPATITIS, CHRONIC; INFUSIONS, INTRAVENOUS; LIVER; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN;

EID: 56149113667     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.619     Document Type: Article

References (20)

1. Ikeda K. Glycyrrhizin injection therapy prevents hepatocellular carcinogenesis in patients with interferon-resistant active chronic hepatitis C. Hepatol Res 2007; 37: S287-S293.
2. Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 2006; 41: 1087-1094.
3. Ikeda K, Arase Y, Kobayashi M, et al. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci 2006; 51: 603-609.
4. Ishida S, Sakiya Y, Ichikawa T, Taira Z. Dose-dependent pharmacokinetics of glycyrrhizin in rats. Chem Pharm Bull 1992; 40: 1917-1920.
5. Ploeger B, Mensinga T, Sips A, Seinen W, Meulenbelt J, DeJongh J. The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev 2001; 33: 125-147.
6. Yamamura Y, Kawakami J, Santa T, et al. Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method. J Pharm Sci 1992; 81: 1042-1046.
7. Shimamura H, Suzuki H, Tagaya O, Horie T, Sugiyama Y. Biliary excretion of glycyrrhizin in rats: kinetic basis for multiplicity in bile canalicular transport of organic anions. Pharm Res 1996; 13: 1833-1837.
8. Ichikawa T, Ishida S, Sakiya Y, Sawada Y. Binding of glycyrrhizin to rat plasma and rat albumin. Chem Pharm Bull 1985; 33: 3031-3033.
9. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 1981; 4: 879-885.
10. Nagase S, Shimamune K, Shumiya S. Albumin-deficient rat mutant: an animal model for analbuminemia. Exp Anim 1980; 29: 33-38.
11. Choi YH, Bae SK, Oh JM, Kim SO, Lee MG. Pharmacokinetics of intravenous methotrexate in mutant nagase analbuminemic rats. Biopharm Drug Dispos 2007; 28: 385-392.
12. Kim EJ, Lee MG. Pharmacokinetics and pharmacodynamics of intravenous torasemide in mutant nagase analbuminemic rats. Biopharm Drug Dispos 2003; 24: 27-35.
13. Iino S, Tango T, Matsushima T, et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res 2001; 19: 31-40.
14. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002; 62: 94-100.
15. Ishida S, Sakiya Y, Ichikawa T, Taira Z, Awazu S. Prediction of glycyrrhizin disposition in rat and man by a physiologically based pharmacokinetic model. Chem Pharm Bull 1990; 38: 212-218.
16. Ichikawa T, Ishida S, Sakiya Y, Sawada Y, Hanano M. Biliary excretion and enterohepatic cycling of glycyrrhizin in rats. J Pharm Sci 1986; 75: 672-675.
17. Yamamura Y, Santa T, Kotaki H, Uchino K, Sawada Y, Iga T. Administration-route dependency of absorption of glycyrrhizin in rats: intraperitoneal administration dramatically enhanced bioavailability. Biol Pharm Bull 1995; 18: 337-341.
18. Nakata T, Kato H, Yano S, Kanaoka M. Pharmacokinetics of glycyrrhizin and glycyrrhetic acid in human after prolonged oral administration. Wakan Yaku 1986; 3: 278-279.
19. Takahashi M, Nakano S, Takeda I, et al. The pharmacokinetics of the glycyrrhizin and glycyrrhetic acid after intravenous administration of glycyrrhizin for the patients with chronic liver disease caused by type C hepatitis virus. Jpn J Gastroenterol 1995; 92: 1929-1936.
20. Ishida S, Sakiya Y, Taira Z. Disposition of glycyrrhizin in the perfused liver of rats. Biol Pharm Bull 1994; 17: 960-969.